{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:20:22Z","timestamp":1793992822204,"version":"4.8.0"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti\u2013epidermal growth factor receptor (EGFR) and anti\u2013vascular endothelial growth factor (VEGF), is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This is a retrospective multicenter observational study that included patients with metastatic SBA treated with anti-EGFR antibodies (cetuximab or panitumumab)\u2009\u00b1\u2009chemotherapy in the first (I) or second (II) line.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirteen patients with metastatic SBA, recruited from 5 Italian referral institutions, were included in the present retrospective analysis. All patients received anti-EGFR inhibitors as a single agent or in association with chemotherapy. More common G2 treatment\u2013related side effects were skin reaction (8 patients, 53.8%), hypomagnesemia (6 patients, 46.2%), and diarrhea (8 patients, 61.5%). Grade 3 diarrhea was observed in only 1 patient. Conjunctivitis was not reported in any patients. Grade 4 toxicity was not reported. In the overall population, median progression-free survival was 5.526\u2009months (95% confidence interval [CI]: 3.684-12.467). Median overall survival was 15.86\u2009months (95% CI: 14.43-24.30). Complete response was observed in 15% of patients, partial response in 39% of patients, stable disease in 23% of patients, and progression disease in 15% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this retrospective analysis, anti-EGFR inhibitors showed to be a suitable addendum to chemotherapy in the I and II line, with an excellent tolerance and safety profile both in I and II line.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1179554920946693","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T07:09:09Z","timestamp":1596524949000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?"],"prefix":"10.1177","volume":"14","author":[{"given":"Emanuela","family":"Dell\u2019Aquila","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Zeppola","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-7540","authenticated-orcid":false,"given":"Marco","family":"Stellato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pantano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Madaudo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[{"name":"Department of Oncology, San Bortolo General Hospital, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Moretto","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Puzzoni","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital and University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio Ken","family":"Garattini","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-9718","authenticated-orcid":false,"given":"Riccardo","family":"Lobefaro","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"bibr1-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)91228-2"},{"key":"bibr2-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/25.4.722"},{"key":"bibr3-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2173-6"},{"key":"bibr4-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.04.013"},{"key":"bibr5-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.132"},{"key":"bibr6-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.03.048"},{"key":"bibr7-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2009.05.037"},{"key":"bibr8-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1097\/01. coc.0000214931.01062.01"},{"key":"bibr9-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32833a86fe"},{"key":"bibr10-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0079"},{"key":"bibr11-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.153866"},{"key":"bibr12-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605898"},{"key":"bibr13-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0568"},{"key":"bibr14-1179554920946693","first-page":"243","volume":"7","author":"Neugut AI","year":"1998","journal-title":"Cancer Epidem Biomar"},{"key":"bibr15-1179554920946693","doi-asserted-by":"publisher","DOI":"10.1159\/000486338"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1179554920946693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1179554920946693","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1179554920946693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:37:18Z","timestamp":1777693038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1179554920946693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":15,"alternative-id":["10.1177\/1179554920946693"],"URL":"https:\/\/doi.org\/10.1177\/1179554920946693","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1179554920946693"}}